Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma

  • Jenifer Vaughan,
  • Moosa Patel,
  • Denise Lawrie,
  • Merriam Machaba,
  • Tracey Wiggill

An error occurred in the coding of 6 of the patients who were lost to follow-up in the survival analysis. These patients were originally coded as having demised, where their outcome was in fact unknown.

This error has had a significant or marginally significant effect on the following results on survival analysis:

  • The median survival time is 4 months (as opposed to the reported 3.5 months).
  • The relationship between survival and the MO-Y parameter is only marginally significant (p-value 0.08 in the global cohort and 0.09 in the people living with HIV), as opposed to the statistically significant result originally reported in the global cohort (p value 0.03).
  • There is a marginally significant association between survival and the HLA-DRlow monocyte count in the people living with HIV (p = 0.07), as opposed to the result lacking any statistical significance originally reported (p = 0.14).
  • The monocyte count is significantly associated with survival in the global cohort (p = 0.04), but not in the people living with HIV (p = 0.11). The monocyte count was originally reported as being marginally significantly associated with survival in the global cohort (p = 0.07), but not in the people living with HIV (p = 0.29).
  • HIV virological suppression is significantly associated with superior survival (p = 0.04). This association was originally reported as being marginally significant (p = 0.06).
  • On Cox Proportional Hazards analysis, the neutrophil count is associated with survival independently from the IPI and CD4 count at a level of 6 x 109/L as opposed to the reported 8 x 109/L.

These changes have little effect on the conclusions of the paper, with the exception of a possible over-interpretation of the potential value of the MO-Y parameter.

The error also resulted in the following changes to the survival analysis which did not impact the statistical significance of the results:

  • With respect to patient age, the p-value changed from 0.87 to 0.86 in the global cohort, but remained unchanged in the patients with HIV.
  • With respect to the IPI score, the p-value changed from 0.001 to 0.0009 in the global cohort, but remained unchanged in the patients with HIV.
  • With respect to disease stage, the p-value changed from 0.054 to 0.077 in the people living with HIV, and was unchanged in the global cohort.
  • With respect to disease stage, the p-value changed from 0.054 to 0.077 in the people living with HIV, and was unchanged in the global cohort.
  • With respect to the presence of extranodal disease the p-value changed from 0.035 to 0.011 in the global cohort, and from 0.16 to 0.2 in the patients with HIV.
  • With respect to the CD4 count, the p-value changed from 0.0008 to 0.004 in the global cohort, and from 0.003 to 0.049 in the patients with HIV.
  • With respect to the LDH level, the p-value changed from 0.06 to 0.25 in the global cohort, and from 0.8 to 0.64 in the patients with HIV.
  • With respect to the Beta-2-microglobulin level, the p-value changed from 0.42 to 0.37 in the global cohort, and from 0.81 to 0.63 in the patients with HIV.
  • With respect to the Neutrophil count, the p-value changed from 0.005 to 0.0002 in the global cohort, and from 0.008 to 0.039 in the patients with HIV.
  • With respect to the L:M ratio, the p-value changed from 0.06 to 0.07 in the global cohort, and from 0.07 to 0.11 in the patients with HIV.
  • With respect to the N:L ratio, the p-value changed from 0.002 to 0.003 in the global cohort, and from 0.005 to 0.013 in the patients with HIV.
  • With respect to the NE-SFL, the p-value changed from 0.06 to 0.11 in the global cohort, and from 0.19 to 0.279 in the patients with HIV.

This has also resulted in errors in Tables 4, 5 and 6. Please see the correct Tables here.

thumbnail
Download:
Table 4. Survival analysis.

https://doi.org/10.1371/journal.pone.0331945.t004

thumbnail
Download:
Table 5. Cox proportional-hazards regression analysis for independent associations between the survival time and the IPI, CD4 count and a neutrophil count >8 x 109/L.

https://doi.org/10.1371/journal.pone.0331945.t005

thumbnail
Download:
Table 6. Cox proportional-hazards regression analysis for independent associations between the survival time and the IPI, CD4 count and a N:L > 6:1.

https://doi.org/10.1371/journal.pone.0331945.t006

A member of the Editorial Board reviewed the corrected findings and advised that they support the results and conclusions reported in the article.

Reference

  1. 1. Vaughan J, Wiggill T, Lawrie D, Machaba M, Patel M. The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma. PLoS One. 2023;18(1):e0280044. pmid:36630466

Citation: Vaughan J, Patel M, Lawrie D, Machaba M, Wiggill T (2025) Correction: The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma. PLoS One 20(9): e0331945. https://doi.org/10.1371/journal.pone.0331945

Published: September 11, 2025

Copyright: © 2025 Vaughan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.